How many drugs treat Malignant tumor of peritoneum?

Drug Landscape tracks 10 marketed treatments for Malignant tumor of peritoneum (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/malignant-tumor-of-peritoneum.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Malignant tumor of peritoneum — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Malignant tumor of peritoneum (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Malignant tumor of peritoneum, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zejula	niraparib	GSK	Poly(ADP-Ribose) Polymerase Inhibitor	Poly [ADP-ribose] polymerase 2	2017-01-01
Lynparza	olaparib	AstraZeneca	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	Poly [ADP-ribose] polymerase 2	2014-01-01
Avastin	bevacizumab	Roche	Vascular Endothelial Growth Factor Inhibitor [EPC]	Vascular endothelial growth factor A	2004-01-01
Bevacizumab	Bevacizumab-Bvzr	Roche	Monoclonal antibody	Vascular Endothelial Growth Factor (VEGF)	2004-01-01
Taxol	paclitaxel	Pfizer	Microtubule Inhibitor [EPC]	Tubulin beta-3 chain	1992-01-01
Taxol	nab-paclitaxel	Pfizer	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01
Taxol	Taxol	M.D. Anderson Cancer Center		Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5
Lynparza	Lynparza	University of Texas Southwestern Medical Center		Mono [ADP-ribose] polymerase PARP16, Tankyrase-1, Tankyrase-2
Avastin	Avastin	Washington University School of Medicine		Vascular endothelial growth factor A
Abraxane	Abraxane	The First Affiliated Hospital with Nanjing Medical University		Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 3 drugs in Malignant tumor of peritoneum
Roche · 2 drugs in Malignant tumor of peritoneum
M.D. Anderson Cancer Center · 1 drug in Malignant tumor of peritoneum
The First Affiliated Hospital with Nanjing Medical University · 1 drug in Malignant tumor of peritoneum
University of Texas Southwestern Medical Center · 1 drug in Malignant tumor of peritoneum
AstraZeneca · 1 drug in Malignant tumor of peritoneum
Washington University School of Medicine · 1 drug in Malignant tumor of peritoneum
GSK · 1 drug in Malignant tumor of peritoneum

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Malignant tumor of peritoneum:

Cite this brief

Drug Landscape (2026). Malignant tumor of peritoneum — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/malignant-tumor-of-peritoneum. Accessed 2026-06-10.

Malignant tumor of peritoneum full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing